Paul Mastoridis

Dr. Mastoridis has 19 years of pharmaceutical industry experience in medical affairs and clinical development, across multiple therapeutic areas. He has a strong background in building medical affairs organizations at global & country levels. Career highlights include the launches of EpiPen (anaphylaxis), Quill SRS (knotless barbed suture device) Clarinex (desloratadine,allergy),Vytorin(ezetimibe/simvastatin, hyperlipidemia) and Nasonex(mometasone, asthma). Paul is currently with Novartis in Cystic Fibrosis helping to establish global product planning and publication, strategic excellence and research in global medical affairs. He has helped guide and successfully launch Tobi Podhaler (tobramycin inhalation powder) in several countries. His passion is developing innovative drug solutions to better patient care. Dr. Mastoridis holds a Doctor of Pharmacy degree and Clinical Research Fellowship in immunosuppressive therapies in transplantation from the University of Minnesota-Minneapolis and a BS in Medical Microbiology from the University of Wisconsin-Madison.